Oncolytic viruses for cancer immunotherapy

被引：0
作者：
Otto Hemminki
João Manuel dos Santos
Akseli Hemminki
机构：
[1] University Health Network and University of Toronto,Division of Urologic Oncology, Department of Surgical Oncology, Princess Margaret Cancer Centre
[2] University of Helsinki,Cancer Gene Therapy Group, Translational Immunology Research Program
[3] Helsinki University Hospital,Department of Urology
[4] TILT Biotherapeutics Ltd,undefined
[5] Helsinki University Hospital Comprehensive Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 13卷
关键词：
Adenovirus; Oncolytic; Tumor; Cancer; Immunotherapy; Review; Immunology; Immune system; Immunosupression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a particular focus on adenoviruses. These serve as a model to elucidate how versatile viruses are, and how they can be used to complement other cancer therapies to gain optimal patient benefits. Historical reports from over a hundred years suggest treatment efficacy and safety with adenovirus and other oncolytic viruses. This is confirmed in more contemporary patient series and multiple clinical trials. Yet, while the first viruses have already been granted approval from several regulatory authorities, room for improvement remains.
引用
收藏
相关论文
共 656 条
[1]  
Lippman SM(2009)Cancer prevention: from 1727 to milestones of the past 100 years Cancer Res 69 5269-5284
[2]  
Hawk ET(2019)Health and sustainability outcomes of vegetarian dietary patterns: a revisit of the EPIC-Oxford and the Adventist Health Study-2 cohorts Eur J Clin Nutr 72 60-70
[3]  
Segovia-Siapco G(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[4]  
Sabate J(2018)Cancer-targeted oncolytic adenoviruses for modulation of the immune system Curr Cancer Drug Targets 18 124-138
[5]  
Bray F(2018)Oncograms visualize factors influencing long-term survival of cancer patients treated with adenoviral oncolytic immunotherapy Mol Ther Oncolytics 9 41-50
[6]  
Ferlay J(2010)Hematopoietic stem cell transplantation: a global perspective JAMA. 303 1617-1624
[7]  
Soerjomataram I(2018)Familial associations in testicular cancer with other cancers Sci Rep 8 10880-830
[8]  
Siegel RL(2019)Second cancers and causes of death in patients with testicular cancer in Sweden PLoS One 14 e0214410-1087
[9]  
Torre LA(2018)The immune landscape of cancer Immunity. 48 812-SS98
[10]  
Jemal A(2017)Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies EMBO Mol Med 9 1067-674
12345678910